Utidelone

DRUG12 trials

Sponsors

Beijing Biostar Pharmaceuticals Co., Ltd., Henan Cancer Hospital, Fudan University, Sun Yat-sen University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Advanced Breast CancerAdvanced and Metastatic Breast CancerBrain MetastasisBreast CancerBreast NeoplasmsHER2-negative Breast CancerHER2-negative Breast Cancer Patients With Brain MetastasesLocally Advanced or Metastatic Breast Cancer

Phase 1

PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer

CompletedNCT05052437

Beijing Biostar Pharmaceuticals Co., Ltd.Advanced and Metastatic Breast Cancer

Start: 2020-10-15End: 2021-02-19Updated: 2023-01-10

Phase 2

Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer

Henan Cancer HospitalSCLC, Extensive Stage

Start: 2021-09-05End: 2023-09-05Target: 40Updated: 2022-03-28

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

Henan Cancer HospitalBreast Cancer

Start: 2022-04-29End: 2024-05-31Target: 100Updated: 2022-09-16

Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Fudan UniversityBreast Neoplasms, Locally Advanced or Metastatic Breast Cancer

Start: 2022-06-10End: 2025-03-09Target: 61Updated: 2022-06-03

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Not yet recruitingNCT05983094

Cancer Institute and Hospital, Chinese Academy of Medical SciencesBreast Cancer, Neoadjuvant Therapy

Start: 2023-09-01End: 2027-09-01Target: 181Updated: 2023-08-09

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

RecruitingNCT06102824

Guangdong Provincial People's HospitalAdvanced Breast Cancer, HER2-negative Breast Cancer

Start: 2024-10-01End: 2028-06-30Target: 252Updated: 2024-11-25

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

RecruitingNCT06125080

Huihua XiongTNBC - Triple-Negative Breast Cancer

Start: 2023-10-30End: 2026-10-30Target: 78Updated: 2023-11-09

Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)

Not yet recruitingNCT06510465

RenJi HospitalBreast Cancer

Start: 2024-08-01End: 2032-03-31Target: 143Updated: 2024-07-19

Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

Not yet recruitingNCT06683703

Beijing Biostar Pharmaceuticals Co., Ltd.Non-small Cell Lung Cancer Patients with Brain Metastases

Start: 2024-12-01End: 2027-12-01Target: 118Updated: 2024-11-12

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

RecruitingNCT06764940

Biostar Pharma, Inc.HER2-negative Breast Cancer Patients With Brain Metastases

Start: 2025-07-14End: 2027-07-15Target: 120Updated: 2025-11-28

A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Not yet recruitingNCT07449481

Tianjin Medical University Cancer Institute and HospitalBrain Metastasis, Malignant Solid Tumor

Start: 2026-05-01End: 2030-02-01Target: 56Updated: 2026-04-01

Phase 3

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

RecruitingNCT05430399

Sun Yat-sen UniversityBreast Neoplasms, Locally Advanced or Metastatic Breast Cancer

Start: 2022-06-21End: 2027-06-01Target: 349Updated: 2023-07-13

Related Papers

Abstract PS5-01-13: Utidelone plus bevacizumab for the treatment of HER2-positive breast cancer brain metastases (U-BOMB-HER): A multicenter, single-arm phase IIstudy

Clinical Cancer Research2026-02-17

Utidelone Plus Bevacizumab for <i>ERBB2</i>-Negative Metastatic Breast Cancer and Active Brain Metastases

JAMA Oncology2025-06-262 citations

Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial.

2024-09-206 citations

Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study.

Journal of Clinical Oncology2024-06-015 citations